Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 1
1992 1
1998 1
2001 1
2003 1
2004 1
2005 1
2006 1
2008 1
2009 3
2010 1
2013 1
2015 1
2016 2
2017 1
2018 1
2019 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, Braiteh F, Waterkamp D, He P, Zou W, Chen DS, Yi J, Sandler A, Rittmeyer A; POPLAR Study Group. Fehrenbacher L, et al. Among authors: artal cortes a. Lancet. 2016 Apr 30;387(10030):1837-46. doi: 10.1016/S0140-6736(16)00587-0. Epub 2016 Mar 10. Lancet. 2016. PMID: 26970723 Clinical Trial.
Opening Windows for Thymic Tumors.
Artal-Cortes AF, Verdún-Aguilar J, Márquez-Medina D. Artal-Cortes AF, et al. J Thorac Oncol. 2023 Feb;18(2):136-138. doi: 10.1016/j.jtho.2022.11.029. J Thorac Oncol. 2023. PMID: 36682839 Free article. No abstract available.
Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.
Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzáles-Larriba JL, Grodzki T, Pereira JR, Le Groumellec A, Lorusso V, Clary C, Torres AJ, Dahabreh J, Souquet PJ, Astudillo J, Fournel P, Artal-Cortes A, Jassem J, Koubkova L, His P, Riggi M, Hurteloup P. Douillard JY, et al. Among authors: artal cortes a. Lancet Oncol. 2006 Sep;7(9):719-27. doi: 10.1016/S1470-2045(06)70804-X. Lancet Oncol. 2006. PMID: 16945766 Clinical Trial.
SEOM clinical guidelines for the treatment of small-cell lung cancer 2013.
Dómine Gómez M, Morán Bueno T, Artal Cortés A, Remon Masip J, Lianes Barragán P; SEOM. Dómine Gómez M, et al. Among authors: artal cortes a. Clin Transl Oncol. 2013 Dec;15(12):985-90. doi: 10.1007/s12094-013-1086-1. Epub 2013 Sep 5. Clin Transl Oncol. 2013. PMID: 24005836 Review.
Patterns of Progression and Feasibility of Re-biopsy After First-line Erlotinib for Advanced EGFR Mutation-positive Non-small-cell Lung Cancer.
Ortega-Granados AL, Artal-Cortes Á, Aguiar-Bujanda D, Oramas J, Fírvida JL, DE Castro J, Fuentes JC, Gordo R, Galán R, Trigo J; ASPET Study Investigators. Ortega-Granados AL, et al. Among authors: artal cortes a. Anticancer Res. 2019 Mar;39(3):1317-1328. doi: 10.21873/anticanres.13244. Anticancer Res. 2019. PMID: 30842164
Prospective randomized phase III trial of etoposide/cisplatin versus high-dose epirubicin/cisplatin in small-cell lung cancer.
Artal-Cortés A, Gomez-Codina J, Gonzalez-Larriba JL, Barneto I, Carrato A, Isla D, Camps C, Garcia-Giron C, Font A, Meana A, Lomas M, Vadell C, Arrivi A, Alonso C, Maestu I, Campbell J, Rosell R. Artal-Cortés A, et al. Clin Lung Cancer. 2004 Nov;6(3):175-83. doi: 10.3816/clc.2004.n.031. Clin Lung Cancer. 2004. PMID: 15555219 Clinical Trial.
21 results